MyVaccineRegister - App/Portal to declare an individual's vaccination against and immunity to COVID-19
MyVaccineRegister - App/Portal to declare an individual's vaccination against and immunity to COVID-19
批准号:
60715
负责人:
金额:
$9.53万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
中文摘要
ImmucheX解决方案是一个实时验证的数据库,适用于每个国家接种COVID-19疫苗的个人,这些人随后接受了病毒检测并登记为对该病毒具有免疫力;这与群体免疫的概念相反-其中受试者暴露于病毒但不一定产生长期免疫力。它将使登记的个人能够恢复正常工作,而不受接触病毒的影响,无论其传播机制如何。它还涉及社会距离问题,因为接种疫苗的人不仅可以保护自己,还可以降低继续传播的风险。ImmucheX项目旨在在政府的健康/公民身份系统和该国任何注册疫苗中工作。鉴于全球有多种疫苗,每个国家可能有不止一种注册疫苗。ImmucheX解决方案旨在适用于任何这些疫苗。一个关键目标是该平台应向所有国家开放,并需要准确快速地提供数据。获得准确的疫苗接种记录和免疫力,经过验证和数字化交付,将使世界能够与COVID-19共存。个人访问将通过ImmucheX移动的应用程序(Android/iOS平台),他们将使用该应用程序来证明他们的免疫力。ImmucheX App的设计首先考虑了隐私,并不收集数据-它只是通过接种疫苗来证明个人的免疫力。
英文摘要
The ImmucheX solution is a real-time verified database for each country of individuals who have received a COVID-19 vaccine, who have subsequently been tested for and registered as having immunity to the virus; this is in contrast to the concept of herd immunity - where a subject has been exposed to the virus but not necessarily generated long-term immunity. It will enable registered individuals to return to normal work and not be affected by coming into contact with the virus, whatever the transmission mechanism. It also deals with the issues of social distancing - since a person who has been vaccinated not only protects themselves, but also reduces the risk of onward transmission.The ImmucheX project is designed to work within a government's health/citizen identity systems and any registered vaccine for that country. Given that there are several vaccines globally, there may be more than one registered vaccine in each country. The ImmucheX solution is designed to work across any of these vaccines.A key objective is that the platform should be open to all nations and it will need to deliver data accurately and speedily.The access to an accurate vaccination record and immunity, verified and digitally delivered, will enable the world to live with COVID-19. Access for the individual is to be via the ImmucheX mobile App (Android/iOS platforms) which they will use to prove their immunity. The ImmucheX App has been designed with privacy first and does not collect data - it is simply to prove an individual's immunity by vaccination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于单细胞和空间转录组分析APP-CD74在衰老泪腺中介导免疫微环境紊乱的机制研究
-
批准号:2026JJ50085
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王万鹏
-
依托单位:
基于GPX4/ACSL4铁死亡通路的 APP 基因突变调控 Aβ 代谢异常在阿尔茨海默病中的作用机制研究
-
批准号:JCZRLH202600691
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
DDAH2在小胶质细胞中调控APP蛋白代谢的新机制及其在阿尔兹海默症中的作用
-
批准号:2026JJ80535
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李俊杰
-
依托单位:
APP细胞间信号介导癌症干细胞与肿瘤细胞的互作驱动肾癌干性特征和肿瘤发生发展的机制研究
-
批准号:JCZRLH202500082
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
电针心包经穴调控PI3K/AKT/GLT-1轴改善APP/PS1双转基因小鼠学习记忆障碍的机制研究
-
批准号:2025JJ60638
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:柯超
-
依托单位:
APP-中医康护现代化技术应用对脑卒中患者健康管理模式的影响效果观察
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:焦迦鸣
-
依托单位:
基于Sirt1介导FoxO3a去乙酰化调控线粒体分裂/融合平衡探讨电针心经穴改善APP/PS1小鼠认知功能障碍的研究
-
批准号:2025JJ60635
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:曹洋
-
依托单位:
OPA1复合杂合突变调控β淀粉样前体蛋白APP导致Behrsyndrome发生的作用机制和神经功能重建研究
-
批准号:QN25H090051
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王呈辉
-
依托单位:
运动皮层-背外侧纹状体神经环路谷氨酸能神经元介导APP/PS1小鼠早期运动技能学习障碍的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:江锦祥
-
依托单位:
乳酸对3月龄APP/PS1小鼠神经元突触丢失的改善作用及分子机制研
究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:张茂
-
依托单位: